Objective: This study aims to examine the relationship between chronic prostatic inflammation and prostatic calculi, and clinical parameters of benign prostatic hyperplasia (BPH). Materials and Methods: This study was based on 225 patients who underwent transurethral resection of the prostate for BPH. Chronic inflammation was graded as 0 (n = 44), I (n = 54), II (n = 88) or III (n = 39) according to severity. Prostatic calculi were classified into types A (n = 66), B (n = 44), M (n = 77) and N (n = 38). The relationship between inflammation and calculus type was analyzed, and clinical parameters of BPH were compared for each group. Results: There was no correlation between severity of inflammation and calculus type. Prostatic volume increased with the severity of inflammation and showed significant differences between G2, G3 and G0. The International Prostate Symptom Score also increased with increasing inflammation. There was no significant difference between each clinical parameter according to calculus type. Conclusions: Prostatic calculi had no significant association with chronic inflamma- tion and clinical parameters of BPH. Chronic inflammation was associated with the volume of the prostate and storage symptoms; thus, it is not only presumed to be related to the progression of BPH, but may also be one of the causes of lower urinary tract symptoms.

Keywords:
Benign prostatic hyperplasia, Calculi, Chronic inflammation, Lower urinary tract symptoms, Prostatic inflammation
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2.
Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ: Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status among Men. Urology 1998;51:578-584.
3.
Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I: Prev-alence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167:1363-1366.
4.
Yoo YN: Prostatitis. Korean J Urol 1994;35:575-585.
5.
Nickel JC: The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol 2006;16:5-10.
6.
Nickel JC, Downey J, Young I, Boag S: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-981.
7.
Moore RA: Morphology of prostatic corpora amylacea and calculi. Arch Pathol 1936;22:22-40.
8.
Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J: Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997;157:1301-1303.
9.
Harada K, Igari D, Tanahashi Y: Gray scale transrectal ultrasonography of the prostate. J Clin Ultrasound 1979;7:45-49.
10.
Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM: The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-89.
11.
Collins MM, Stafford RS, O'Leary MP, Barry MJ: How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-1228.
12.
Kohnen PW, Drach GW: Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979;121:755-760.
13.
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS: The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the reduce trial. Eur Urol 2008;54:1379-1384.
14.
Lee SY, Park YY: Clinical characteristics of the associated histopathological findings in benign prostatic hyperplasia. Korean J Urol 1991;32:915-920.
15.
Klimas R, Bennett B, Gardner WA Jr: Prostatic calculi: a review. Prostate 1985;7:91-96.
16.
Ho KL, Segura JW: Lower urinary tract calculi; in Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds): Campbell-Walsh Urology. Philadelphia, Saunders, 2007, vol 3, pp 2663-2673.
17.
Lee SE, Ku JH, Park HK, Jeong CK, Kim SH: Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol 2003;170:745-748.
18.
Shoskes DA, Lee CT, Murphy D, Kefer J, Wood HM: Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2007;70:235-238.
19.
Geramoutsos I, Gyftopoulos K, Perimenis P, Thanou V, Liagka D, Siamblis D, Barbalias G: Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults. Eur Urol 2004;45:333-337, discussion 337-338.
20.
Fox M: The natural history and significance of stone formation in the prostate gland. J Urol 1963;89:716-727.
21.
Vilches J, Lopez A, De Palacio L, Munoz C, Gomez J: SEM and X-ray microanalysis of human prostatic calculi. J Urol 1982;127:371-373.
22.
Leader AJ, Queen DM: Prostatic calculous disease. J Urol 1958;80:142-146.
23.
Meares EM Jr: Infection stones of prostate gland. Laboratory diagnosis and clinical management. Urology 1974;4:560-566.
24.
Finkle AL: Genito-urinary tract infection, prostatic calculi and carcinoma of the prostate. J Urol 1954;71:67-81.
25.
Nickel JC: Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol 1994;1:1-4.
26.
Emberton M, Elhilali M, Matzkin H, Har-ving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G: Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005;66:316-322.
27.
Stoner E: The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375-378.
28.
Kaplan SA, Te AE, Pressler LB, Olsson CA: Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 1995;154:1764-1769.
29.
Lee SO, Cho IR, Lee KC, Kim HS: Elevation of serum prostate specific antigen in subclinical prostatitis: the role of pathology of inflammation. Korean J Urol 2006;47:31-36.
30.
Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME: Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007;100:327-331.
31.
Kramer G, Marberger M: Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006;16:25-29.
32.
St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ: Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760-768.
33.
Lee KL, Peehl DM: Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172:1784-1791.
34.
Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V: Inflammation and chronic prostatic disease: evidence for a link? Eur Urol 2007;52:964-972.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.